On Feb. 28, 2024, the U.S. Centers for Disease Control and Preventionﾒs (CDC) Advisory Committee on Immunization Practices (ACIP) voted in favor (11 to 1; 1 abstain) to recommend that individuals aged 65 and older should receive an additional dose of 2023-2024 Formula COVID-19 vaccine at least four months after the initial 2023-2024 COVID-19 dose.

ACIPﾒs recommendation was subsequently endorsed by the CDC. Doses of the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) are available at major retail pharmacies nationwide and can be ordered through one of our distribution partners for physician use in the non-retail setting.